CEVAXEL RTU 50 mg/ml Suspension for Injection

Main information

  • Trade name:
  • CEVAXEL RTU 50 mg/ml Suspension for Injection
  • Pharmaceutical form:
  • Suspension for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CEVAXEL RTU 50 mg/ml Suspension for Injection
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Ceftiofur
  • Therapeutic area:
  • Cattle, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0218/001
  • Authorization date:
  • 13-02-2012
  • EU code:
  • FR/V/0218/001
  • Last update:
  • 09-08-2016

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

A.LABELLING

PARTICULARSTOAPPEARONTHEOUTERPACKAGE

PARTICULARSTOAPPEARONTHEIMMEDIATEPACKAGE

Cardboardboxesof100&250ml

Vialsof100&250ml

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Cevaxel-RTU50mg/ml,suspensionforinjectionforcattleandpigs

Ceftiofur

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

1vialcontains:

Ceftiofur(ashydrochloride) 50mg/ml

3. PHARMACEUTICALFORM

Suspensionforinjection.

4. PACKAGESIZE

100ml

250ml

5. TARGETSPECIES

Cattleandpigs.

6. INDICATION(S)

Readthepackageleafletbeforeuseanddisposal.

7. METHODANDROUTE(S)OFADMINISTRATION

Cattle:Subcutaneoususe.

Pigs:Intramuscularuse.

Readthepackageleafletbeforeuseanddisposal.

8. WITHDRAWALPERIOD

Meat&offal:

Pigs:5days.

Cattle:8days

Milk:0hours

9. SPECIALWARNING(S),IFNECESSARY

Penicillinsandcephalosporinsmayoccasionallycausesevereallergicreactions.Seepackageleafletfor

userwarnings.

10. EXPIRYDATE

EXP:

Oncebroached,useby:___/___/___

Shelf-lifeafterfirstopening:28days.

11. SPECIALSTORAGECONDITIONS

Keepthevialintheoutercartoninordertoprotectfromlight.

12. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSOR

WASTEMATERIALS,IFANY

Readpackageleafletbeforeuseanddisposal.

13. THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSOR

RESTRICTIONSREGARDINGSUPPLYANDUSE,ifapplicable

Foranimaltreatmentonly.

Tobesuppliedonlyonveterinaryprescription.

14. THEWORDS“KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keepoutofthereachandsightofchildren.

15. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

16. MARKETINGAUTHORISATIONNUMBER(S)

17. MANUFACTURER’SBATCHNUMBER

Lot:

B.PACKAGELEAFLET

PACKAGELEAFLET

Cevaxel-RTU50mg/ml,suspensionforinjectionforcattleandpigs

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERAND

OFTHEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFOR

BATCHRELEASE,IFDIFFERENT

Marketingauthorisationholder:

Manufacturerforthebatchrelease:

CevaSantéAnimale-10,av.deLaBallastière-33500Libourne-France

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Cevaxel-RTU50mg/ml,suspensionforinjectionforcattleandpigs

Ceftiofur

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENT(S)

1vialcontains:

Ceftiofur(ashydrochloride) 50mg/ml

4. INDICATION(S)

Infectionsassociatedwithbacteriasensitivetoceftiofur.

Incattle:

ForthetreatmentofbacterialrespiratorydiseaseassociatedwithPasteurellamultocida,

MannheimiahaemolyticaandHaemophilussomnus.

Forthetreatmentofacuteinterdigitalnecrobacillosis(panaritium,footrot),associatedwith

FusobacteriumnecrophorumandBacteroidesmelaninogenicus(Porphyromonas

asaccharolytica).

Fortreatmentofthebacterialcomponentofacutepost-partum(puerperal)metritiswithin10daysafter

calvingassociatedwithEscherichiacoli,ArcanobacteriumpyogenesandFusobacterium

necrophorum:thisindicationisrestrictedtocaseswheretreatmentwithanotherantimicrobialhas

failed

Inpigs:

ForthetreatmentofbacterialrespiratorydiseaseassociatedwithPasteurellamultocida,

ActinobacilluspleuropneumoniaeandStreptococcussuis.

5. CONTRAINDICATIONS

Donotadministertoananimalpreviouslyfoundtobehypersensitivetoceftiofurandother 

-lactam

antibiotics.

Donotuseincaseofknownresistancetoothercephalosporinsorbeta-lactamantibiotics.

Donotuseinpoultry(includingeggs)duetoriskofspreadofantimicrobialresistancetohumans.

6. ADVERSEREACTIONS

Hypersensitivityreactionsunrelatedtodosecanoccur.Allergicreactions(e.g.skinreactions,

anaphylaxia)mayoccasionallyoccur.Incaseoftheoccurrenceofallergicreactionthetreatment

shouldbewithdrawn.

Inpigs,mildreactionsattheinjectionsite,suchasdiscolorationofthefasciaorfat,havebeenobserved

insomeanimalsforupto20daysafterinjection.

Incattle,mildinflammatoryreactionsattheinjectionsite,suchastissueoedema,thickeningof

connectivetissueanddiscolorationofthesubcutaneoustissueand/orfascialsurfaceofthemusclemay

beobserved.Clinicalresolutionisreachedinmostanimalsby10daysafterinjectionalthoughslight

tissuediscolorationmaypersistfor28daysormore.

7. TARGETSPECIES

Cattleandpigs.

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOF

ADMINISTRATION

Cattle:Subcutaneoususe

-Respiratorydisease:1mgceftiofur(ashydrochloride)/kg/dayfor3to5days,i.e.1ml/50kgateach

injection.

-Acuteinterdigitalnecrobacillosis:1mgceftiofur(ashydrochloride)/kg/dayfor3days,i.e.1ml/50kg

ateachinjection.

-Acutepost-partummetritiswithin10daysaftercalving:1mgceftiofur(ashydrochloride)/kg/dayfor

5consecutivedays,i.e.1ml/50kgateachinjection.

Incaseofacutepost-partummetritis,additionalsupportivetherapymightberequiredinsomecases.

Pigs:Intramuscularuse

3mgceftiofur(ashydrochloride)/kg/dayfor3days,i.e.1ml/16kgateachinjection.

Shakethebottlewellbeforeusetobringtheproductbackintosuspension.

Toensureacorrectdosage,bodyweightshouldbedeterminedasaccuratelyaspossibleinorderto

avoidunder-dosing.Subsequentinjectionsmustbegivenatdifferentsites.

Asthevialcannotbebroachedmorethan50times,theusershouldchoosethemoreappropriatevial

size.

9. ADVICEONCORRECTADMINISTRATION

10. WITHDRAWALPERIOD

Cattle:

Meatandoffal:8days.

Milk:zerohours.

Pigs:

Meatandoffal:5days.

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Keepthevialintheoutercartoninordertoprotectfromlight.

Shelf-lifeafterfirstopeningthevial:28days.

DonotuseaftertheexpirydatewhichisstatedonthecartonafterEXP.

12. SPECIALWARNING(S)

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Penicillinsandcephalosporinsmaycausehypersensitivity(allergy)followinginjection,inhalation,

ingestionorskincontact.Hypersensitivitytopenicillinsmayleadtocrossreactionstocephalosporins

andviceversa.Allergicreactionstothesesubstancesmayoccasionallybeserious.

-Donothandlethisproductifyouknowyouaresensitisedorifyouhavebeenadvisednottowork

withsuchpreparations.

-Handlethisproductwithgreatcaretoavoidexposure.Washhandsafteruse.

-Ifyoudevelopsymptomsfollowingexposure,suchasaskinrash,youshouldseekmedicaladviceand

showthedoctorthiswarning.

Swellingoftheface,lipsoreyesordifficultywithbreathingaremoreserioussymptomsandrequire

urgentmedicalattention.

Donotuseasprophylaxisincaseofretainedplacenta.

Pregnancyandlactation

Studiesinlaboratoryanimalshavenotproducedanyevidenceofteratogenic,foetotoxicor

maternotoxiceffects.Thesafetyoftheproducthasnotbeenestablishedinsowsorcowsduring

pregnancyandlactation.

Useonlyaccordingtoabenefit/riskassessmentbytheresponsibleveterinarian.

Interactionwithothermedicinalproductsandotherformsofinteraction

Thebactericidalpropertiesofcephalosporinsareantagonizedbysimultaneoususeofbacteriostatic

antibiotics(macrolides,sulfonamidesandtetracyclines).

Overdose

Thelowtoxicityofceftiofurhasbeendemonstratedinpigsusingceftiofursodiumatdosesinexcessof

8timestherecommendeddailydoseofceftiofurintramuscularlyadministeredfor15consecutivedays.

Incattle,nosignsofsystemictoxicityhavebeenobservedfollowingsubstantialparenteral

overdosages.

Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

UseofCevaxelRTUmayconstitutearisktopublichealthduetospreadofantimicrobial

resistance.

CevaxelRTUshouldbereservedforthetreatmentofclinicalconditionswhichhaverespondedpoorly,

orareexpectedtorespondpoorlytofirstlinetreatment.Official,nationalandregionalantimicrobial

policiesshouldbetakenintoaccountwhentheproductisused.Increaseduse,includinguseofthe

productdeviatingfromtheinstructionsgiven,mayincreasetheprevalenceofresistance.Whenever

possible,CevaxelRTUshouldonlybeusedbasedonsusceptibilitytesting.

13. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIAL,IFANY

Disposeofanyunusedproductandemptycontainersinaccordancewithguidancefromyourlocalwaste

regulationauthority.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

15. OTHERINFORMATION

Packsizes:

Cardboardboxcontainingone100mlvial

Cardboardboxcontainingone250mlvial

Notallpacksizesmaybemarketed.

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration